1-2 of 2
Hagen S. Bachmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma

Johannes H. Schulte, Hagen S. Bachmann, Bent Brockmeyer, Katleen DePreter, André Oberthür, Sandra Ackermann, Yvonne Kahlert, Kristian Pajtler, Jessica Theissen, Frank Westermann, Jo Vandesompele, Frank Speleman, Frank Berthold, Angelika Eggert, Benedikt Brors, Barbara Hero, Alexander Schramm, Matthias Fischer
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5082–5092.
https://doi.org/10.1158/1078-0432.CCR-10-2809
Published: 31 July 2011
View article titled, High <em>ALK</em> Receptor Tyrosine Kinase Expression Supersedes <em>ALK</em> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Open the PDF for High <em>ALK</em> Receptor Tyrosine Kinase Expression Supersedes <em>ALK</em> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

The AA Genotype of the Regulatory BCL2 Promoter Polymorphism (−938C>A) Is Associated with a Favorable Outcome in Lymph Node–Negative Invasive Breast Cancer Patients

Hagen S. Bachmann, Friedrich Otterbach, Rainer Callies, Holger Nückel, Maja Bau, Kurt W. Schmid, Winfried Siffert, Rainer Kimmig
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5790–5797.
https://doi.org/10.1158/1078-0432.CCR-06-2673
Published: 01 October 2007
View article titled, The AA Genotype of the Regulatory <em>BCL2</em> Promoter Polymorphism (−938C&gt;A) Is Associated with a Favorable Outcome in Lymph Node–Negative Invasive Breast Cancer Patients
Open the PDF for The AA Genotype of the Regulatory <em>BCL2</em> Promoter Polymorphism (−938C>A) Is Associated with a Favorable Outcome in Lymph Node–Negative Invasive Breast Cancer Patients in another window